Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Combined With Ivonescimab in Patients With Squamous Non-Small Cell Lung Cancer

NCT07614646 is registered in ClinicalTrials.gov with Everest Medicines (Beijing) Co., Ltd. as lead sponsor.

NCT NCT07614646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07614646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Combined With Ivonescimab in Patients With Squamous Non-Small Cell Lung Cancer
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
July 31, 2028
Enrollment
13 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

squamous non-small cell lung cancer sqnsclc